Abstract. The maintenance of telomere length has been hypothesized to be involved in the early steps of cancerogenesis. A physiologic modulation of telomere maintenance is exerted by TRF1 (telomeric-repeat binding factor-I), which deletion permits telomere elongation. Gastrointestinal neoplastic (n=19) and non-neoplastic tissues (six inflammatory disease and six normal mucosa distant from tumor at least 5 cm) were studied, by immunohistochemistry, for TRF1 expression, by using a polyclonal antibody antiTRF1. Differentiated and not proliferating epithelial secretory cells (Ki67 and p53 negative cells) were stained by anti-TRF1, which did not stain tumor cells in all cases but one (p<O.OOOl). p53 was expressed by 26% of tumor cases. Inflammatory gastrointestinal non-tumor tissues showed lower expression of TRF1 in epithelial secreting cells compared to normal tissues (p=0.008). These preliminary data suggest that down-regulation of the TRF1 expression in tumor cells may be involved in cell immortalization as an initial step in gastrointestinal carcinogenesis (before p53 alteration), and may open new perspectives, when confirmed, in gastrointestinal tumor prognosis.
Introduction
Telomeres are nucleoprotein complexes consisting of long tandem arrays of short G-rich sequence motifs (TT AGGG repeats) packaged by specific DNA binding proteins, required for the protection and replication of chromosome ends. In human somatic cells, telomeres shorten with successive cell divisions, due to the terminal sequence loss that accompanies DNA replication. Significant telomere shortening is associated with progressive genomic instability and widespread cell death (1), via p53 dependent and independent mechanisms (2, 3) .
In cancer cells, telomeres are usually shorter than in the corresponding normal cells, with further shortening during tumor progression (3) (4) (5) (6) (7) and telomere maintenance activation usually follows telomere shortening (3, 5, 7, 8) . In fact telomerase or alternative telomere maintenance (AL T) activation, is showed to be (9-11) an important event in the multistage carcinogenesis (3, 5, 12) . However, the impact of telomere dysfunction on immortalization and tumorigenesis is complex and only partially understood.
Human telomeres are bound to the telomere-specific proteins (TRF1 and TRF2) (13) (14) (15) (16) (17) that control chromosome stability and telomere length (17) . TRF1, a ubiquitously expressed protein present at telomeres throughout the cell cycle, is proposed to be an inhibitor of telomerase (18, 19) , by sequestration of the 3' telomere terminus in TRF1-and TRF2-induced telomeric loops (17) .
Overexpression of TRF 1 has been associated to a gradual and progressive telomere shortening (14, 17, 18) , whereas telomere elongation is induced by expression of a dominantnegative TRF1 mutant that inhibits binding of endogenous TRF1 to telomeres (14) .
Telomerase up-regulation is considered a late event during carcinogenesis of the esophagus, stomach, and intestine (20) , occurring later than telomere shortening, K-ras mutation, but earlier than p53 mutation (21) . While telomerase is active in most cancers, conflicting results exist regarding its expression in normal tissues and premalignant lesions (20, 22, 23) . Telomerase is constitutively expressed in permanently renewing epithelia along the gastrointestinal tract and, contrary to other reports, it does not appear to be increased in pre-neoplastic lesions (20) . Moreover the methods used are expensive, time consuming, the exact location and frequency of telomerase-positive cells are difficult to identify, results are some time-conflicting, and it is not practical to set a general cutoff level for cancer diagnosis (22, 23) . The activation of the alternative mechanisms involved in telomere maintenance seems to complicate the interpretation of results.
Because telomerase is a late event with respect to telomere shortening we evaluated the expression of TRF 1, a modulator of telomere maintenance, in gastrointestinal neoplastic and nonneoplastic tissues, and its possible role as prognostic marker. 
Materials and methods

TRFI immunoreactivity stains normal cells and rarely neoplastic cells (only one case)
. The stained cells were negative for Ki67, p53, CD31, having the morphology of differentiated non-proliferating cells (Table I , Fig. 1 ). The immunoreactivity was localized mainly to the nucleus and occasionally in the cytoplasm.
-
ARAGONA et at: TRFI EXPRESSION IN GASTROINTESTINAL TUMORS
Endoscopic samples of 31 patients with gastroenterological pathologies (5 gastric cancer, 14 colorectal cancer, 6 chronic gastritis, 6 normal samples, at least 5 cm from cancer) have been evaluated for TRFI expression by immunohistochemistry.
Immunohistochemistry. TRFI expression was assessed by using a goat polyclonal antibody anti-TRF 1 (Santa Cruz Biotecnology, w.d. 1:100); the proliferative activity by the monoclonal anti-Ki67 (a marker for cell cycling, Dako, w.d. 1:100); the neo-angiogenesis by the monoclonal anti-CD31 (a marker of activated endothelial cells, Novocastra, w.d. 1:100); the altered p53 expression by the monoclonal anti-p53 (Novocastra, w.d. 1:50).
As revealing system second antibody-biotin-streptavidineperoxidase-AEC system (Universal Quick Kit, Vector) was used.
Briefly endoscopic specimens were mounted in OCT compound and cryosectioned to 5-µ thickness with a 2800 Frigocut Cryostat (Reichert-lung, Germany). Tissue sections were mounted on glass slides and fixed in ice cold acetone for 5 min. Each section was then rinsed 3 times in phosphate buffered saline (PBS), incubated for 5 min in 3% hydrogen peroxide (HzOz) to inhibit endogen peroxidase and then incubated overnight at 4 .C, with the primary antibodies against TRFl, Ki67, CD31, p53. After rinsing 3 times in PBS, sections were incubated (15 min at room temperature) with a biotinylated anti-mouse goat antibody (Universal Quick Kit, Vector); rinsed 3 times in PBS, then labeled (15 min at room temperature) with streptavidin conjugated horseradish peroxidase (Universal Quick Kit, Vector). Sections were stained in brown with Aminoetilcarbazole (AEC, Vector), counter stained with hematoxylin and mounted. As negative control we substituted the primary antibody with nonimmune serum. Samples were than observed with a Zeiss photomicroscope. Immunoreactivity was grated by using a scale of 0-3+, with 0 representing no detectable stain and 3+ represents the strongest stain. The histotype and percentage of stained cells were also recorded. CD31 expression was scored as the number of stained capillary/endothelial cells in the area of higher CD31 positive cells [Hot Spot, microvessel density (MVD)] (24).
Statistics. Student's t-test (T) and rank correlation tests (r) were used. Statistical differences were considered significant for p<0.05.
Results
Controls.
In normal tissues the anti-TRFI antibody stained intensely almost all intraglandular muciparous (secretory) cells (mean intensity 2. 17:t0.75) in 6 out of 6 cases of normal mucose distant >5 cm from tumor ( Fig. 1) . In the other control cases with inflammatory diseases 4 out of 6 cases displayed lower mean intensity of TRFI expression (mean intensity 0.67±0.82) (T=3.3; p=0.008). The basal epithelial cells were TRFI negative and frequently Ki67 positive. Vascular endothelial cells were also stained by anti-TRFI antibody without significant differences between the two groups of controls (mean intensity 1.75±l.22) . No staining was observed for CD31 and p53.
Tumor cases. Tumor cells were TRFI negative, or weakly positive in one case out of 19 (5.3%) and localized in Ki67 negative cells (Table  I) : the significance with respect to both controls were highly significant: T=11.2; p<0.00001 and T=3.8; p=0.0007 (Table I, Figs.  2 and 3) .
In 5 out of the 19 cases (26%) tumor cells were positive for p53. The case that expressed TRFI was p53 negative. CD31 was expressed in 10 out of 19 cases (53%) with a mean MVD = 84.7:t53.4 (Fig. 2) .
Inside the tumor area TRFI was expressed by epithelial intraglandular muciparous cells (secretory) at lower mean intensity 0.69:t0.7 (T=4.3; p=0.0003) and in lower number of cases (9 out of 19 cases =47%; Fisher test: p=0.028) with respect to the epithelial cells of the non-neoplastic area (>5 cm from tumor) ( Table I) . Some endothelial cells were also stained in 14 out of 19 cases (74%) (mean 2.17:t0.86) (Table I) , with no differences with respect to controls. TRFI Telomeres, in colon cancer, are frequently shorter than those of non neoplastic tissues (3) (4) (5) 7, 8) and increased telomerase activity occurs after extensive telomere shortening (7). Telomerase is highly expressed in gastrointestinal cancers (7, 23, (25) (26) (27) with respect to non cancerous tissues (23) , with gradual activation during the course of colorectal carcinogenesis (26) .
While telomerase activation is considered an hallmark of cancer cells (4), this is a late event (20, 21) , during the long and multistep carcinogenesis process, with respect to telomere shortening. Within the physiologic molecules involved in the mechanisms of telomere maintenance a major role is played by TRF1, a ubiquitously expressed protein that control telomere length (18, 19) . On the contrary with respect to increased expression of telomerase in cancer cells, a reduced expression of TRF 1 (point mutation or deletion) is showed to induce telomere elongation and extend cell survival (14) .
In the present study, for the first time, the expression of TRF 1 has been demonstrated in gastrointestinal tissues and especially in differentiated not proliferating epithelial secretory cells (Ki67 negative), endothelial cells (CD31 and Ki67 negative), and wild-type p53 expressing cells (p53 negative). In gastrointestinal tumor samples no expression of TRF 1 was observed in tumor cells (94.7% of cases were negative), whereas p53 was expressed in the 26% of cases. This observation may suggest that TRF1 down-regulation may precede p53 alteration.
Inflammatory gastrointestinal non-tumor tissues have shown reduced expression of TRF1 in epithelial secreting cells with respect to normal gastrointestinal muciparous cells.
These observations of changing in the TRF1 expression pattern (reduction in neoplastic cells and in chronic inflamed tissues) probably express a mechanism able to extend the proliferative potential of epithelial and tumor cells and, may be one of the initial steps in gastrointestinal carcinogenesis.
Confirmation on larger study of the physiologic role of TRF1 in acceleration of cellular aging (telomere shortening and cell cycle checkpoints switching on), or extention of cellular survival, may open new perspectives in the prognostic evaluation of gastrointestinal carcinogenesis. Figure I . Normal colon mucosa, distant more than 10 cm from the tumor (adenocarcinoma of descending colon). The intraglandular muciparous (secretory) cells are stained intensely by anti-TRFI antibody (brown), whereas the basal epithelial cells are TRFI negative (xIOO). In this case TRFI scored with strong intensity, whereas p53 and CD31 were negative. positive cells were always negative for Ki67, CD31 or p53. Parietallymph nodes were TRF1 negative. Discussion Figure. 2. Case of rectal adenocarcinoma (x250). The neo-angiogenesis, as expressed by CD31 positive endothelial cells (brown), was high (MDV > 150). TRFI was negative in tumor cells and also in intraglandular secretory cells. p53 was negative. Figure 3 . Graphic expression of the mean intensity of TRFI expression in epithelial cell from normal mucosa and inflammatory mucosa (controls), epithelial secretory cells in the tumor area and tumor cells. Statistical differences (Student's t-test) between groups were significant for p<0.05.
